Litcius/Paper detail

EZH2 as an Epigenetic Regulator of Cardiovascular Development and Diseases

Jiali Yuan, Chengye Yin, Ying-Ze Li, Shuai Song, Guojian Fang, Qunshan Wang

2021Journal of Cardiovascular Pharmacology31 citationsDOI

Abstract

ABSTRACT: Enhancer of zeste homolog 2(EZH2) is an enzymatic subunit of polycomb repressive complex 2 (PRC2) and is responsible for catalyzing mono-, di-, and trimethylation of histone H3 at lysine-27(H3K27me1/2/3). Many noncoding RNAs or signaling pathways are involved in EZH2 functional alterations. This new epigenetic regulation of target genes is able to silence downstream gene expression and modify physiological and pathological processes in heart development, cardiomyocyte regeneration, and cardiovascular diseases, such as hypertrophy, ischemic heart diseases, atherosclerosis, and cardiac fibrosis. Targeting the function of EZH2 could be a potential therapeutic approach for cardiovascular diseases.

Topics & Concepts

EZH2PRC2EpigeneticsBiologyHistoneHistone H3RegulatorRegulation of gene expressionEnhancerCell biologyCancer researchGene expressionGeneGeneticsCongenital heart defects researchEpigenetics and DNA MethylationCongenital Heart Disease Studies
EZH2 as an Epigenetic Regulator of Cardiovascular Development and Diseases | Litcius